Breast Cancer Recurrence DNA Assay In Development; Exagen Targets HCV
This article was originally published in The Gray Sheet
Executive Summary
Exagen Diagnostics is working with FDA to design a pivotal trial assessing whether results from an earlier study of the firm's breast cancer recurrence genomic test can be duplicated in a larger cohort